India, Aug. 26 -- Eris Lifesciences Limited, a leading Indian branded formulations company, announced that its sterile injectable manufacturing facility in Ahmedabad, operated by subsidiary Swiss Parenterals (acquired in 2024), has received approval from ANVISA, Brazil's national health regulator.
The approval follows a successful inspection of Swiss Parenterals' two injectable facilities conducted by ANVISA in April 2025. The company expects approval for the second facility soon. Both facilities are already certified by EU GMP and PIC/s, and currently supply products across Latin American markets including Mexico, Chile, Argentina, and Peru.
With the ANVISA nod, Eris plans to launch injectable products in Brazil, strengthening its presen...